Dr Teo Zui Chih (Rachel)
Renal Physician
Specialty
Renal Medicine
Languages
English, Mandarin
Gender
Female
Insurance Panel
Prudential^, HSBC Life, Singlife
Please check with your insurance provider for more information, and for their most up-to-date list of panel doctors.
^Specialists may qualify to be on the Extended Panel (EP). You may enjoy selected panel benefits depending on your policy and riders.
Contact our call centre
Experience
Dr Rachel Teo is a renal physician at Mount Elizabeth Hospital, Singapore.
Her specialty interests are chronic kidney disease, dialysis, glomerular diseases, and kidney transplantation. She also manages patients with chronic kidney disease and those requiring dialysis treatment.
Prior to private practice, Dr Teo worked at the National University Hospital (NUH) as a consultant nephrologist where, in addition to nephrology, she worked in the transplant unit and provided care to pre- and post-transplant patients. She also was a consultant nephrologist at the National Kidney Foundation (NKF) Singapore.
Dr Teo graduated from the University of Sydney, Australia. She went on to complete physician training in renal medicine and general medicine, and was granted fellowship of the Royal Australasian College of Physicians, Australia. She worked at Sydney’s tertiary hospitals with acute transplant units, where she developed an interest in kidney transplantation and pursued further training to become well-versed in transplant medicine.
During her time at NUH, she was the patient safety officer responsible for morbidity and mortality reviews, peer-review learning and hospital safety audits. While she was at NKF, in addition to providing care for patients on dialysis treatment, she ran the chronic kidney disease intervention clinic, focused on screening and education of the public who are at risk for kidney disease, with the aim of early detection and treatment of diabetes and hypertension to prevent and delay progression to kidney disease.
She has a keen research interest with several publications in kidney transplantation. She is also a reviewer for international peer-reviewed transplant journals.
Dr Teo served as an executive committee member of the Society of Organ Transplantation, Singapore and continues to be a member of the Australasian and New Zealand Society of Nephrology.
Besides her clinical work, she is an adjunct assistant professor at Duke-NUS Medical School and Yong Loo Lin School of Medicine.
Research & publications
Teo, R. Z. C., Ng, A. L. C., See, V., Yan, H., Singh, T., & Khan, B. (2023). Sucroferric oxyhydroxide use in patients on haemodialysis – real-world experience from an Asian cohort. Proceedings of Singapore Healthcare, 32.
Teo, R. Z. C., So, W. Z., Ooi, L. Y., Goh, B., Lu, J., Vathsala, A., Thamboo, T. P., & Tiong, H. Y. (2022). Multi‐photon microscopy for the evaluation of interstitial fibrosis in extended criteria donor kidneys: A proof‐of‐concept study. Clinical Transplantation, 36(8).
Teo, R. Z. C., Khan, B., Singh, T., & Ng, A. L. C. (2022). Health economics of kidney replacement therapy in Singapore: Taking stock and looking ahead. Annals Academy of Medicine Singapore, 51(4), 236–240.
Teo, R. Z. C., Kaur, D., Ong, D., Singh, T., & Khan, B. (2022). Implementation of exercise therapy in kidney failure. Renal Society of Australasia Journal, 18(1).
Teo, R. Z. C., & Da, Y., Vathsala, A. (2021). Invasive fungal infection by Volvariella volvacea: First reported case following solid organ transplantation and a unique therapeutic approach. Transplant Infectious Disease, 23(4).
Teo, R. Z. C., Chang, Z. Y., Tambyah, P. A., Lum, L., & Vathsala, A. (2022). Tailoring management and immunosuppression regimen in kidney transplant recipients with COVID-19 infection: lessons from Singapore. Singapore Medical Journal, 63(12), 759.
Teo, R. Z. C., et al. (2020). Defining the structural basis for human leukocyte antigen reactivity in clinical transplantation. Scientific Reports, 10(1).
Teo, R. Z. C., et al. (2019). Defining the structural basis for human alloantibody binding to human leukocyte antigen allele HLA-A*11:01. Nature Communications, 10(1).
